These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis. Zhang WH, Zhang SY, Hou QQ, Qin Y, Chen XZ, Zhou ZG, Shu Y, Xu H, Hu JK. Front Oncol; 2020 Jul 14; 10():1214. PubMed ID: 32983960 [Abstract] [Full Text] [Related]
6. Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C, Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J. Br J Cancer; 2018 Aug 14; 119(4):424-428. PubMed ID: 29872148 [Abstract] [Full Text] [Related]
8. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer. Li J, Zhang Y, Hu D, Gong T, Xu R, Gao J. Aging (Albany NY); 2020 Jul 15; 12(14):14271-14284. PubMed ID: 32668412 [Abstract] [Full Text] [Related]
9. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. World J Gastroenterol; 2015 Oct 28; 21(40):11428-38. PubMed ID: 26523107 [Abstract] [Full Text] [Related]
11. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients. Chen L, Shi Y, Yuan J, Wu Q, Han Y, Qin R, Jia B, Wei B, Wei L, Dai G, Jiao S. Med Oncol; 2014 Sep 28; 31(9):159. PubMed ID: 25119501 [Abstract] [Full Text] [Related]
14. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach. Hashimoto T, Ogawa R, Tang TY, Yoshida H, Taniguchi H, Katai H, Oda I, Sekine S. Mod Pathol; 2019 Apr 28; 32(4):568-575. PubMed ID: 30425335 [Abstract] [Full Text] [Related]
16. RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. Yang H, Hong D, Cho SY, Park YS, Ko WR, Kim JH, Hur H, Lee J, Kim SJ, Kwon SY, Lee JH, Park DY, Song KS, Chang H, Ryu MH, Cho KS, Kang JW, Kook MC, Thiessen N, He A, Mungall A, Han SU, Kim HK. Nat Commun; 2018 Oct 25; 9(1):4439. PubMed ID: 30361512 [Abstract] [Full Text] [Related]
18. Signet ring cell cancer of stomach and gastro-esophageal junction: molecular alterations, stage-stratified treatment approaches, and future challenges. Kumar NAN, Jose A, Usman N, Rajan K, Munisamy M, Shetty PS, Rao M. Langenbecks Arch Surg; 2022 Feb 25; 407(1):87-98. PubMed ID: 34505199 [Abstract] [Full Text] [Related]